Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
LUND, Sweden, April 14, 2014 (GLOBE NEWSWIRE) -- The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place at 5 p.m. on Thursday, May...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Styrelsen för Active Biotech AB (publ) har...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} The Board of Directors of Active Biotech AB...
-
LUND, Sweden, April 7, 2014 (GLOBE NEWSWIRE) -- Active Biotech's Annual Report 2013 (in Swedish) is now available for download at www.activebiotech.com. The English version will be available within...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Active Biotechs årsredovisning för 2013 finns nu...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Active Biotech's Annual Report 2013 (in Swedish)...
-
LUND, Sweden, Feb. 19, 2014 (GLOBE NEWSWIRE) -- Active Biotech (NASDAQ OMX NORDIC: ACTI) today announces that its partner Teva Pharmaceuticals (NYSE: TEVA), has decided not to proceed to the...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund den 19 februari, 2014 - Active Biotech...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund, Sweden, February 19, 2014 - Active...
-
LUND, Sweden, Feb. 13, 2014 (GLOBE NEWSWIRE) -- Laquinimod Teva remains committed to the development of laquinimod (NERVENTRA®) for the treatment of multiple sclerosis (MS) On...